Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2019 /
Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies

29th Mar - 3rd Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 1137

Dr James Gulley - National Cancer Institute, Bethesda, USA

Dr James Gulley speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about a study looking at M7824 (a bifunctional fusion protein targeting TGF-β and PD-L1) in patients with HPV-associated malignancies.

Dr Gulley reports patients with HPV-associated malignancies saw around a 35% response rate and patients with HPV-confirmed malignancies seeing closer to a 40% response rate.

He also points to a 12 month overall survival of above 50% and that response was maintained in 11 out of 15 patients suggesting that there is really good activity in these patients.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation